CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy

J. I. Friedman, T. Vrijenhoek, S. Markx, I. M. Janssen, W. A. Van Der Vliet, B. H.W. Faas, N. V. Knoers, W. Cahn, R. S. Kahn, L. Edelmann, K. L. Davis, J. M. Silverman, H. G. Brunner, A. G. Van Kessel, C. Wijmenga, R. A. Ophoff, J. A. Veltman

Research output: Contribution to journalArticlepeer-review

239 Scopus citations


A homozygous mutation of the CNTNAP2 gene has been associated with a syndrome of focal epilepsy, mental retardation, language regression and other neuropsychiatric problems in children of the Old Order Amish community. Here we report genomic rearrangements resulting in haploinsufficiency of the CNTNAP2 gene in association with epilepsy and schizophrenia. Genomic deletions of varying sizes affecting the CNTNAP2 gene were identified in three non-related Caucasian patients. In contrast, we did not observe any dosage variation for this gene in 512 healthy controls. Moreover, this genomic region has not been identified as showing large-scale copy number variation. Our data thus confirm an association of CNTNAP2 to epilepsy outside the Old Order Amish population and suggest that dosage alteration of this gene may lead to a complex phenotype of schizophrenia, epilepsy and cognitive impairment.

Original languageEnglish
Pages (from-to)261-266
Number of pages6
JournalMolecular Psychiatry
Issue number3
StatePublished - Mar 2008


  • Copy number variation
  • Epilepsy
  • Schizophrenia


Dive into the research topics of 'CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy'. Together they form a unique fingerprint.

Cite this